Home
Storia in 3 fonti
Novartis to buy Avidity Biosciences for $12bn
Deal for specialist in rare diseases is biggest acquisition under chief executive Vas Narasimhan
- ·
cnbc.com
Novartis is in talks to buy U.S. biotech firm Avidity Biosciences for more than $70 a share, Bloomberg News reports
Swiss pharmaceutical giant Novartis is nearing a deal to buy biotechnology company Avidity Biosciences for more than $70 a share, Bloomberg News reported.
- ·
ft.com
Novartis to buy Avidity Biosciences for $12bn
Deal for specialist in rare diseases is biggest acquisition under chief executive Vas Narasimhan
- ·
ilsole24ore.com
Novartis comprerà Avidity Biosciences per 12 miliardi di dollari
L’operazione, che riguarda una società specializzata nelle malattie rare, è la più grande acquisizione realizzata sotto la guida dell’amministratore delegato Vas Narasimhan
- ·
Chinese drugmakers shift from copycats to global innovators
Reforms, faster development and lower costs have turbocharged growth
- ·
Big pharma’s scramble over the patent cliff will be costly
Groups will need to buy mature biotechs to replace revenue lost to generic competitors
- ·
Thermo Fisher nears $10bn takeover of drug trial software maker Clario
Deal for Nordic Capital-owned group would mark one of the biggest private equity exits of the year